Search clinical trials for: recurrent ovarian epithelial cancer

Total 97440 results

Peking University Cancer Hospital & Institute

Recruiting

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

China
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Undifferentiated Carcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Undifferentiated Carcinoma and other conditions
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Ovarian Cancer

China
PhotonPharma, Inc.

Not yet recruiting

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer

Ovarian Cancer
ImmunoGen, Inc.

Not yet recruiting

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Recurrent Ovarian Cancer | Folate Receptor-Alpha Positive

United States, Spain, Australia, Belgium, Canada, France, Ireland, Italy
Dana-Farber Cancer Institute
ImmunityBio, Inc.

Not yet recruiting

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Ovarian Cancer | Platinum-resistant Ovarian Cancer | Ovarian Carcinoma | Recurrent Ovary Cancer | Ovarian Carcinoma, Recurrent

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian Cancer

China
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Ovarian Cancer | Epithelial Ovarian Cancer | Ovary Neoplasm | Recurrent

United States
University of Washington
National Cancer Institute (NCI)

Recruiting

Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
The University of Hong Kong

Recruiting

Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer (SCENIC)

Recurrent Ovarian Carcinoma

Hong Kong
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Cervical Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Renal Pelvis Cancer | Urinary Bladder Neoplasm | Recurrent...

United States
Chang Gung Memorial Hospital

Recruiting

Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer

Ovarian Cancer

Taiwan
The First Affiliated Hospital of Xiamen University

Not yet recruiting

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Ovarian Cancer
RemeGen Co., Ltd.

Not yet recruiting

RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Primary Peritoneal Cancer | Fallopian Tube | Epithelial Ovarian

China
Qilu Hospital of Shandong University

Not yet recruiting

The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients

Ovarian Cancer Recurrent
Kancera AB
Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Recruiting

A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (KANDOVA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Denmark, Norway, Sweden
Verastem, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)

Low Grade Serous Ovarian Cancer

United States, Australia
Power Life Sciences Inc.

Not yet recruiting

Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients

Recurrent Ovarian Cancer

United States
A2 Biotherapeutics Inc.
Tempus AI

Recruiting

A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2)

Cancer | Colorectal Cancer | Ovarian Neoplasms | Ovarian Cancer | NSCLC | Lung Cancer | Rectal Cancer | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Colon Cancer | Pancreas Cancer | Colorectal Adenocarcinoma | Solid Tumor, Adult | CRC | Pancreatic Neoplasm | Ovary Cancer | NSCLC, Recurrent | Non-Small Cell... and other conditions

United States
Yonsei University

Not yet recruiting

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) (DOVE)

Uterine Cervical Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Vulvar Cancer | Clear Cell Carcinoma | Vagina Neoplasm
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Ovarian Cancer Recurrent

China
Hebei Medical University Fourth Hospital

Not yet recruiting

A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer

Epithelial Ovarian Cancer

China
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Not yet recruiting

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy (SOPRANO)

Ovarian Cancer Recurrent

United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Ovarian Endometrioid Adenocarcinoma | Endometrial Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | Endometrial Low Grade Endometrioid... and other conditions

United States
Lan Coffman
National Cancer Institute (NCI); MorphoSys AG

Recruiting

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Recurrent Ovarian Cancer

United States
Mayo Clinic

Recruiting

A Study of FRaDCs for Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube Carcinosarcoma | Primary Peritoneal Carcinosarcoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian... and other conditions

United States
Sapience Therapeutics

Recruiting

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Hepatocellular Carcinoma | Pancreatic Cancer | Ovarian Cancer | Cholangiocarcinoma | Triple Negative Breast Cancer | Metastatic Melanoma | Colon Cancer | Synovial Sarcoma | Breast Cancer Metastatic | Metastatic Colon Cancer | Melanoma Stage IV | Melanoma Recurrent | TNBC - Triple-Negative Breast Cancer | NSCLC, Metastatic and other conditions

United States
Fudan University

Not yet recruiting

The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab

Recurrent Ovarian Cancer

China
NX Development Corp

Not yet recruiting

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

Ovarian Cancer
Onxeo

Recruiting

Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors

Breast Cancer | Metastatic Castration-resistant Prostate Cancer | Recurrent Epithelial Ovarian Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Recurrent Platinum-Resistant Ovarian Carcinoma | Metastatic Fallopian Tube Carcinoma | Metastatic Primary... and other conditions

United States
Tongji Hospital
Qilu Hospital of Shandong University; People's Hospital of Quzhou; Shenzhen Hua...

Not yet recruiting

Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer (K19017-004)

Ovarian Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma

United States
Karyopharm Therapeutics Inc
GOG Foundation; European Network of Gynaecological Oncological Trial Groups... and other collaborators

Recruiting

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)

Endometrial Cancer

United States, Belgium, Spain, Israel, Australia, Italy, Georgia, Ireland, Greece, Slovakia, Canada, Hungary, Czechia, Germany
Sham Sunder Kakar
University of Louisville Health Care

Recruiting

Combination Therapy for Recurrent Ovarian Cancer

Recurrent Ovarian Cancer

United States
Verismo Therapeutics

Recruiting

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Ovarian Cancer | Mesothelioma, Malignant | Cholangiocarcinoma Recurrent

United States
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma

United States, Puerto Rico
Chongqing University Cancer Hospital

Recruiting

Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi

Ovarian Cancer

China
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Recurrent Endometrial Endometrioid Adenocarcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Metastatic Endometrial Endometrioid Adenocarcinoma

United States
ImmunoGen, Inc.

Recruiting

First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

United States
University of Oklahoma
GlaxoSmithKline

Recruiting

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation (ARID1A)

Recurrent Ovarian Carcinoma | Recurrent Endometrial Carcinoma | ARID1A Gene Mutation

United States
Haider Mahdi
Merck Sharp & Dohme LLC; ALX Oncology

Recruiting

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

Ovarian Cancer

United States
Yonsei University

Recruiting

Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation.

Ovarian Cancer

Korea, Republic of
Yonsei University

Recruiting

Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer (SABR-ROC)

Recurrent Epithelial Ovarian Cancer

Korea, Republic of
Zhongda Hospital

Not yet recruiting

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Ovarian Cancer, Epithelial

China
Peking Union Medical College Hospital
Zai Lab (Shanghai) Co., Ltd.

Not yet recruiting

A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi (t)

Epithelial Ovarian Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

Platinum-resistant Recurrent Ovarian Cancer

China
H. Lee Moffitt Cancer Center and Research Institute
Anixa Biosciences, Inc.

Recruiting

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

Ovarian Cancer

United States
National Cancer Center, Korea

Recruiting

HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-HIPEC-02)

Epithelial Ovarian Cancer

Korea, Republic of

Search clinical trials for: recurrent ovarian epithelial cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations